AIM ImmunoTech (LTS:0A4Y) FCF Margin % : -9,053.33% (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. AIM ImmunoTech's Free Cash Flow for the three months ended in Dec. 2024 was $-4.07 Mil. AIM ImmunoTech's Revenue for the three months ended in Dec. 2024 was $0.05 Mil. Therefore, AIM ImmunoTech's FCF Margin % for the quarter that ended in Dec. 2024 was -9,053.33%.

As of today, AIM ImmunoTech's current FCF Yield % is -314.16%.

The historical rank and industry rank for AIM ImmunoTech's FCF Margin % or its related term are showing as below:

LTS:0A4Y' s FCF Margin % Range Over the Past 10 Years
Min: -12438.35 Med: -8799.97 Max: -1832.95
Current: -9084.71

During the past 13 years, the highest FCF Margin % of AIM ImmunoTech was -1832.95%. The lowest was -12438.35%. And the median was -8799.97%.

LTS:0A4Y's FCF Margin % is ranked worse than
92.29% of 999 companies
in the Biotechnology industry
Industry Median: -120.51 vs LTS:0A4Y: -9084.71

AIM ImmunoTech FCF Margin % Historical Data

The historical data trend for AIM ImmunoTech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech FCF Margin % Chart

AIM ImmunoTech Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-6,725.77

-10,813.33

-11,616.31

-10,817.82

-9,084.71

AIM ImmunoTech Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-15,012.31	-12,162.50	-6,474.00	-9,337.14	-9,053.33

Competitive Comparison of AIM ImmunoTech's FCF Margin %

For the Biotechnology subindustry, AIM ImmunoTech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's FCF Margin % falls into.

Save Embed

;

Save Embed

;

AIM ImmunoTech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

AIM ImmunoTech's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-15.444	/	0.17
	=	-9,084.71 %

AIM ImmunoTech's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-4.074	/	0.045
	=	-9,053.33 %

AIM ImmunoTech FCF Margin % Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

AIMI:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).

AIM ImmunoTech Headlines

No Headlines